iSpecimen reports Q3 EPS ($2.10) vs ($4.66) last year

Reports Q3 revenue $2.66M vs $2.78M last year. “The third quarter was a period of continued strategic transformation for iSpecimen (ISPC), primarily driven by several key initiatives,” said Tracy Curley, CEO of iSpecimen. “First, we completed a 1-for-20 reverse stock split which helped the Company maintain its Nasdaq listing. Additionally, we secured a $1,000,000 loan facility with favorable terms, an agreement which included access to an additional $1,000,000 revolving credit line tied to a future $5,000,000 financing, which we successfully completed on October 31, 2024.”